AR046784A1 - Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima - Google Patents
Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultimaInfo
- Publication number
- AR046784A1 AR046784A1 ARP040104479A ARP040104479A AR046784A1 AR 046784 A1 AR046784 A1 AR 046784A1 AR P040104479 A ARP040104479 A AR P040104479A AR P040104479 A ARP040104479 A AR P040104479A AR 046784 A1 AR046784 A1 AR 046784A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- substituted
- group
- cycloalkyl
- alkyl
- Prior art date
Links
- -1 CYCLINE AMINE Chemical class 0.000 title abstract 14
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000002541 furyl group Chemical group 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000001041 indolyl group Chemical group 0.000 abstract 5
- 125000001624 naphthyl group Chemical group 0.000 abstract 5
- 125000004076 pyridyl group Chemical group 0.000 abstract 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 5
- 150000003254 radicals Chemical group 0.000 abstract 5
- 125000001544 thienyl group Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 abstract 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 2
- 229960004373 acetylcholine Drugs 0.000 abstract 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 abstract 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 abstract 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 abstract 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 abstract 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 abstract 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010061876 Obstruction Diseases 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 abstract 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229950000688 phenothiazine Drugs 0.000 abstract 1
- 125000002071 phenylalkoxy group Chemical group 0.000 abstract 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940113082 thymine Drugs 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
- 229940075420 xanthine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un compuesto de amina cíclica que tiene la fórmula (1), en la que: cuando X e Y carbonos, n es 0, 1, 2 ó 3; m es 1, 2, ó 3; p es 0, 1 ó 2; cuando X es oxígeno e Y es carbono, n es 1; m es 2; y p es 1; cuando X es carbono e Y es nitrógeno, n es 2; m es 1; y p es 2; W es O, S, o NH; U es NR3, O, o un enlace; R3 se selecciona entre el grupo compuesto por hidrógeno, alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior, fenilo sustituido o no sustituido, o fenil sustituido o no sustituido(C1-3)alquilo inferior; donde, cuando está sustituido, un grupo está sustituido con uno o más radicales seleccionado entre el grupo compuesto por alcoxi C1-8, halo, hidroxi, amino, ciano, trifluorometilo, alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8 y cicloalquil(C3-8)-alquilo inferior; q es un entero de 0 a 7; h es 0, 1, ó 2; g es 1, 2, ó 3; V se selecciona entre el grupo compuesto por fenilo, tiofenilo, furanilo, piridinilo, naftilo, quinolinilo, indolilo, benzotiofenilo, y benzofuranilo; R4 se selecciona entre el grupo compuesto por hidrógeno, hidroxi, amino, halo, ciano, trifluorometilo, alcoxi C1-8, alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)alquilo inferior, fenilo, fenilalquilo inferior (C1-3), COR6, COOR6, CONHR6, CON(R6)2, NHR6, N(R6)2, y G; k es un entero de 0 a 5; T se selecciona entre el grupo compuesto por uno de los siguientes grupos sustituidos o no sustituido: fenilo, mono, di, y tri sustituido, tiofenilo, furanilo, piridinilo, naftilo, quinolinilo, indolilo, benzotiofenilo, pirrol, tiazol, imidazol, pirazol, triazol, oxazol, isoxazol, furacan, benzofuranilo, isoindol, indazol, carbazol, bencimidazol, indolizina, purina, adenina, guanina, xantina, cafeína, ácido úrico, azepina, piridina, piridazina, pirazina, pirimidina, triazina, pirimidona, uracilo, citosina, timina, isoquinolina, ftalazina, pteridina, naftiridina, acridina, cinolina, fenazina, quinazolina, fenoxazina, quinoxalina, fenotiazina; donde, cuando está sustituido, un grupo está sustituido con uno más radicales seleccionado entre el grupo compuesto por alcoxi C1-8, halo, hidroxi, amino, trifluorometilo, alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)alquilo inferior, fenilo y fenilalquilo inferior (C1-3); R5 se selecciona entre el grupo compuesto por COOR6, CONHR6, COR6, CON(R6)2, COG, oxadiazolilo sustituido o no sustituido, oxazolilo sustituido o no sustituido, imidazolilo sustituido o no sustituido, fenoxi sustituido o no sustituido, o ciano; donde, cuando está sustituido, un grupo está sustituido con uno o más radicales seleccionado entre el grupo compuesto por alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)alquilo inferior, fenilo y fenilalquilo inferior (C1-3), alcoxi C1-8, halo, hidroxi, amino, ciano y trifluorometilo; G se selecciona entre el grupo compuesto por uno de los siguientes grupo sustituido o no sustituido; pirrolidinilo, piperidinilo, dihidroindolilo, tetrohidroquinolinilo, morfolino, azetidinilo, hexahidroazepinilo, o octahidroazocinilo; donde cuando está sustituido, un grupo está sustituido con uno o más radicales seleccionado entre el grupo compuesto por alcoxi C1-8, hidroxi, amino, alquilo C1-8, ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior, fenilo y fenilalquilo inferior (C1-3); y R1 se selecciona entre el grupo compuesto por uno de los siguientes grupos sustituido o no sustituido: hidrógeno, fenilo, fenilalquilo inferior (C1-6), tiofenilo, tiofenilalquilo inferior (C1-6), furanilo, furanil-alquilo inferior(C1-6), piridinilo, piridinil-alquilo inferior (C1- 6), imidazolilo, imidazolil-alquilo inferior(C1-6), naftilo, naftil-alquilo inferior (C1-6), quinolinilo, quinolinil-alquilo inferior(C1-3), indolilo, indolil-alquilo inferior(C1-6), benzotiofenilo, benzotiofenil-alquilo inferior(C1-6), benzofuranilo, benzofuranil-alquilo inferior(C1-6), benzoimidazolilo, benzoimidazolil-alquilo inferior(C1-6), alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior(C1-6), o alquenilo C3-8; donde, cuando está sustituido, un grupo está sustituido con uno o más radicales seleccionados entre el grupo compuestos por alcoxi C1-8, fenoxi, fenilalcoxi (C1-3), halo, hidroxi, amino, ciano, trifluorometilo, metilenodioxi, etilenodioxi, propilenodioxi, butilenodioxi, alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)alquilo inferior, fenilo, fenilalquilo inferior(C1-3) tiofenilo, tiofenil-alquilo inferior(C1-3), furanilo, furanil-alquilo inferior(C1-3), piridinilo, piridinil-alquilo inferior(C1-3), naftilo, naftil-alquilo inferior(C1-3) quinolinilo, quinolinil-alquilo inferior(C1-3), indolilo, indolil-alquilo inferior(C1-3), benzotiofenilo, benzotiofenil-alquilo inferior(C1-3), benzofuranilo, benzofuranil- alquilo inferior(C1-3), COOH, COR6, COOR6, CONHR6, CON(R6)2, COG, NHR6, N(R6)2, G, OCOR6, OCONHR6, NHCOR6, N(R6)COR6, NHCOOR6 y NHCONHR6; o una sal farmacéuticamente aceptable. Composición farmacéutica para el tratamiento de enfermedades mediadas por el receptor muscarínico de acetilcolina, que comprende un compuesto de la fórmula (1) y un vehículo farmacéuticamente aceptable del mismo. Uso de un compuesto de la fórmula (1) para preparar una composición farmacéutica para inhibir la unión de acetilcolina a sus receptores en un mamífero en necesidad del mismo, siendo efectiva preferentemente para tratar una enfermedad mediada por el receptor muscarínico de acetilcolina, en el que la acetilcolina se une a dicho receptor. La enfermedad puede ser enfermedad pulmonar obstructiva crónica, bronquitis crónica, asma, obstrucción respiratoria crónica, fibrosis pulmonar, enfisema pulmonar y rinitis alérgica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52682403P | 2003-12-03 | 2003-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046784A1 true AR046784A1 (es) | 2005-12-21 |
Family
ID=34676665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104479A AR046784A1 (es) | 2003-12-03 | 2004-12-01 | Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070179184A1 (es) |
| EP (1) | EP1708702A2 (es) |
| JP (1) | JP2007513181A (es) |
| KR (1) | KR20060123415A (es) |
| AR (1) | AR046784A1 (es) |
| AU (1) | AU2004296207A1 (es) |
| BR (1) | BRPI0417215A (es) |
| CA (1) | CA2549272A1 (es) |
| IL (1) | IL175995A0 (es) |
| IS (1) | IS8515A (es) |
| MA (1) | MA28217A1 (es) |
| MX (1) | MXPA06006372A (es) |
| NO (1) | NO20062992L (es) |
| PE (1) | PE20050897A1 (es) |
| UY (1) | UY28645A1 (es) |
| WO (1) | WO2005055940A2 (es) |
| ZA (1) | ZA200604395B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045914A1 (es) * | 2003-07-17 | 2005-11-16 | Glaxo Group Ltd | Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima |
| EA200600787A1 (ru) * | 2003-10-17 | 2006-08-25 | Глэксо Груп Лимитед | Антагонисты мускариновых ацетилхолиновых рецепторов |
| TW200524577A (en) * | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| EP1725236A4 (en) * | 2004-03-11 | 2009-05-13 | Glaxo Group Ltd | NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS |
| EP1725564A4 (en) * | 2004-03-17 | 2007-09-12 | Glaxo Group Ltd | ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR |
| WO2005094251A2 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3muscarinic acetylcholine receptor antagonists |
| MY144753A (en) | 2004-04-27 | 2011-10-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| JP2007537261A (ja) * | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| CA2573185A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| MX2007000762A (es) | 2004-07-22 | 2007-04-02 | Ptc Therapeutics Inc | Tienopiridinas para tratamientode hepatitis c. |
| EP1778229A4 (en) * | 2004-08-10 | 2009-06-17 | Incyte Corp | AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS |
| WO2006055553A2 (en) * | 2004-11-15 | 2006-05-26 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| JP2009503099A (ja) * | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| WO2007022351A2 (en) * | 2005-08-18 | 2007-02-22 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| CL2009000249A1 (es) | 2008-02-06 | 2009-09-11 | Glaxo Group Ltd | Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis. |
| TW201000476A (en) | 2008-02-06 | 2010-01-01 | Glaxo Group Ltd | Dual pharmacophores-PDE4-muscarinic antagonistics |
| AR070564A1 (es) | 2008-02-06 | 2010-04-21 | Glaxo Group Ltd | Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232978A (en) * | 1988-12-23 | 1993-08-03 | Merck Patent Gesellschaft Mit Beschrankter Haftung | 1-(2-arylethyl)-pyrrolidines |
| JP2002518483A (ja) * | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | β−アミロイドペプチド放出を阻害するための化合物および／またはその合成 |
| US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
-
2004
- 2004-12-01 AR ARP040104479A patent/AR046784A1/es unknown
- 2004-12-01 PE PE2004001185A patent/PE20050897A1/es not_active Application Discontinuation
- 2004-12-01 UY UY28645A patent/UY28645A1/es unknown
- 2004-12-03 EP EP04813055A patent/EP1708702A2/en not_active Withdrawn
- 2004-12-03 JP JP2006542825A patent/JP2007513181A/ja active Pending
- 2004-12-03 MX MXPA06006372A patent/MXPA06006372A/es unknown
- 2004-12-03 WO PCT/US2004/040667 patent/WO2005055940A2/en active Application Filing
- 2004-12-03 US US10/581,230 patent/US20070179184A1/en not_active Abandoned
- 2004-12-03 AU AU2004296207A patent/AU2004296207A1/en not_active Abandoned
- 2004-12-03 CA CA002549272A patent/CA2549272A1/en not_active Abandoned
- 2004-12-03 BR BRPI0417215-9A patent/BRPI0417215A/pt not_active Application Discontinuation
- 2004-12-03 KR KR1020067013265A patent/KR20060123415A/ko not_active Application Discontinuation
-
2006
- 2006-05-29 IL IL175995A patent/IL175995A0/en unknown
- 2006-05-30 ZA ZA200604395A patent/ZA200604395B/en unknown
- 2006-06-02 MA MA29068A patent/MA28217A1/fr unknown
- 2006-06-19 IS IS8515A patent/IS8515A/xx unknown
- 2006-06-27 NO NO20062992A patent/NO20062992L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20062992L (no) | 2006-06-27 |
| MXPA06006372A (es) | 2006-08-23 |
| ZA200604395B (en) | 2007-10-31 |
| KR20060123415A (ko) | 2006-12-01 |
| JP2007513181A (ja) | 2007-05-24 |
| IL175995A0 (en) | 2006-10-05 |
| AU2004296207A1 (en) | 2005-06-23 |
| WO2005055940A3 (en) | 2005-09-15 |
| MA28217A1 (fr) | 2006-10-02 |
| UY28645A1 (es) | 2005-06-30 |
| EP1708702A2 (en) | 2006-10-11 |
| US20070179184A1 (en) | 2007-08-02 |
| PE20050897A1 (es) | 2005-11-06 |
| IS8515A (is) | 2006-06-19 |
| BRPI0417215A (pt) | 2007-02-21 |
| WO2005055940A2 (en) | 2005-06-23 |
| CA2549272A1 (en) | 2005-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046784A1 (es) | Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
| JP7216682B2 (ja) | Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物 | |
| AU2016373533B2 (en) | Novel compounds | |
| CN102388032B (zh) | 作为ccr3拮抗剂的取代的哌啶 | |
| JP6367366B2 (ja) | ４−アミノ−イミダゾキノリン化合物 | |
| CN1080260C (zh) | 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途 | |
| CN113412259A (zh) | 通过泛素蛋白酶体途径降解btk的双官能化合物 | |
| JP5257068B2 (ja) | 保護されていてもよい酸性基を含有する化合物およびその用途 | |
| EP2931717B1 (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
| JP2019513135A (ja) | Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体 | |
| NO20062648L (no) | Calcitonin gen relaterte peptid reseptor antagonister | |
| CN107001389A (zh) | 用作可溶性鸟苷酸环化酶活化剂的三唑并吡嗪基衍生物 | |
| BRPI0612888A2 (pt) | anilino-piridinotriazinas cìclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica | |
| CN1950082A (zh) | 双环和桥连的含氮杂环化物 | |
| US8058292B2 (en) | Therapeutic agents useful for treating pain | |
| CN1829708A (zh) | 哌啶化合物和含有它们的药物组合物 | |
| BRPI0618752A2 (pt) | derivados de pirimidona bicìclica substituìda | |
| JP7140920B2 (ja) | ＪＡＫ阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリジン化合物およびその使用 | |
| CA2749174A1 (en) | Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses | |
| TW201722936A (zh) | Ｃｇｒｐ受體拮抗劑 | |
| AU2012210718A1 (en) | Pyrazole compounds as CRTH2 antagonists | |
| Schirok et al. | Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors | |
| CN1946696A (zh) | 四氢吡喃基环戊基1－取代的和1,1－二取代的四氢异喹啉趋化因子受体活性调节剂 | |
| WO2020120606A1 (en) | New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions | |
| Luo et al. | Calcitonin gene-related peptide (CGRP) receptor antagonists: Heterocyclic modification of a novel azepinone lead |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |